Diabetic nephropathy: Renoprotective effects of GLP1R agonists and SGLT2 inhibitors

Nature Reviews Nephrology, Published online: 9 October 2017; doi:10.1038/nrneph.2017.140

New data from the LEADER trial show that the glucagon-like peptide 1 receptor agonist liraglutide protects against diabetic nephropathy in patients with type 2 diabetes mellitus. The renoprotective efficacy of liraglutide is not, however, as great as that reported for the sodium-glucose cotransporter 2 inhibitor emplagiflozin in the EMPA-REG OUTCOME trial.

中文翻译：

---

糖尿病肾病：GLP1R激动剂和SGLT2抑制剂的肾脏保护作用

糖尿病肾病：GLP1R激动剂和SGLT2抑制剂的肾脏保护作用

Nature Reviews Nephrology，在线发布：2017年10月9日；doi：10.1038 / nrneph.2017.140

LEADER试验的新数据表明，胰高血糖素样肽1受体激动剂利拉鲁肽可预防2型糖尿病患者的糖尿病肾病。但是，利拉鲁肽的肾脏保护功效不如EMPA-REG OUTCOME试验中报道的钠-葡萄糖共转运蛋白2抑制剂依普拉替洛嗪的。